Background: Transition of patients care between settings presents an increased opportunity for errors and preventable morbidity. A number of studies outlined that pharmacy-led medicine reconciliation (MR) might facilitate safer information transfer and medication use. MR practice is not well standardized and often delivered in combination with other health care activities. The question regarding the effects and costs of pharmacy-led MR and the optimum MR practice is warranted of value. Objectives: To review the evidence for the effects and costs/cost-effectiveness of complete pharmacy-led MR in hospital settings. Methods: A systematic review searching the following database was conducted up to the 13th December 2015; EMBASE & MEDLINE Ovid, CINAHL and the Cochrane library. Studies evaluating pharmacy-led MR performed fully from admission till discharges were included. Studies evaluated non-pharmacy-led MR at only one end of patient care or transfer was not included. Articles were screened and extracted independently by two investigators. Studies were divided into those in which: MR was the primary element of the intervention and labeled as "primarily MR" studies, or MR combined with non-MR care activities and labeled as "supplemented MR" studies. Quality assessment of studies was performed by independent reviewers using a pre-defined and validated tool. Results: The literature search identified 4065 citations, of which 13 implemented complete MR. The lack of evidence precluded addressing the effects and costs of MR. Conclusions: The composite of optimum MR practice is not widely standardized and requires discussion among health professions and key organizations. Research focused on evaluating cost-effectiveness of pharmacy-led MR is lacking.
Introduction
Transition of patient care between settings presents an increased opportunity for error. Poor communication of clinical information at health care transitions is responsible for over 50% of all medication errors and up to 20% of adverse events. 1e4 At least half of discrepancies at discharge originate from discrepancies in medication histories, and 72% of all potentially harmful discrepancies in admission or discharge orders were due to errors related to compiling preadmission medicines list. 5, 6 It is also estimated that 12% of adverse drug events upon hospital admission were related to medicine use and that each adverse event increase hospital stay by 8.5 days on average. 3, 7 Medicine reconciliation (MR) is proposed as a solution for communication deficits between health care settings. 2,8e10 In the US, the Joint Commission for health care organizations accreditation defines MR as the process of "obtaining and maintaining an accurate, detailed list of all medicines taken by a patient and using this list to provide correct medicines anywhere within the health care system." 10 In the UK, MR is described similarly and Abbreviation: MR, medicine reconciliation. Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. There are no financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work.
recommended to be performed every time a transfer of care takes place. 11 Studies have outlined that MR facilitates safer medication use after patient transfer of care. 12e18 Of note, two systematic reviews of hospital-based MR, Kwan et al, 17 and Mueller et al, 18 supported MR interventions that relied on pharmacists to improve the transfer of medication information. It was highlighted also that MR when bundled with other health care activities such as medication review and discharge planning might improve clinical and health care utilization post discharge. 17 However, the cost/costeffectiveness of MR was not fully addressed, and MR was not always fully implemented. Thus, little was concluded whether the observed beneficial effects may justify costs and what would be the composites of optimized MR practice. The Institute of Healthcare Improvement stated that occasionally MR is not fully implemented. For some organizations, MR is widely accepted as a medication history-taking task, and in others it includes only discharge reconciliation. 19 MR continues to be a challenge for many hospitals and care settings. This is due to the lack of clear ownership of MR and the need for developing a standardized approach to implement MR. 19 Thus, exploring the existing evidence to identify the features of MR practice and the resources necessary to deliver is warranted. This systematic review aimed to synthesize evidence to determine the effects and costs associated with complete MR; in which MR is implemented at admission and continued through the hospital stay until discharge and where patient information is fully and accurately communicated to the next health provider. This would enable service purchasers and health policymakers to make more informed decisions regarding MR optimum practice and cost implications.
Methods

Identification of studies
PRISMA guidelines were used to inform this systematic review. A literature search was carried out from the start date of the database (noted in parentheses) to 13th December 2015. The following databases were reviewed; EMBASE (1946) & MEDLINE Ovid (1950) , CINAHL (1961) and the Cochrane library including Cochrane Database of Systematic Review (1988), Database of Abstracts of Reviews of Effects and the NHS Economic Evaluation Database (1991), the Centre of Reviews and Dissemination and PHARMLINE provided by the National electronic Library for Medicines (1970) .
Search terms were set by the authors prior to the beginning of the electronic search. Scoping searches reviewing published MR articles and citation searches using the SCOPUS database were conducted to identify all relevant search terms. Search terms were discussed with peer researchers with mixed professional and research backgrounds in an open forum. Search terms were revised accordingly. Bibliographies and reference lists of the identified studies and systematic reviews were revised to identify additional relevant articles. Authors and key institutions including the UK National Patient Safety Agency and National Prescribing Centre, Institute of Healthcare Improvement, the Agency of Healthcare research and Quality and Joint Commission in the US were contacted by email to obtain any relevant work. Search terms included: medicine/medication reconciliation, medical record review or assessment, drug history-taking, seamless care plus information communication and care transfer. Truncations (*), wild cards ($), hyphens and other relevant Boolean operators were used where permitted. The search strategy (Appendix 1) is available upon request. No restriction on language or publication date was applied.
Non-English studies were translated to English language by an independent researcher who speaks fluently in several languages.
Inclusion and exclusions criteria
Eligible studies were those evaluating adults and children receiving pharmacy-led MR within hospital inpatient settings. All types of admissions and ward specialties were considered. Only studies describing clearly that MR was implemented fully upon admission through the hospital stay until discharge and with patient information being communicated accurately to the next health provider were included. The term 'complete MR' was used for this review. Studies evaluating non-pharmacy-led MR at only one end of patient care or transfer were not included. Studies evaluating pharmacy-led MR using a qualitative approach and studies evaluating enhanced interventions, including telephone helpline and post discharge follow-up calls, were excluded. Telephone helpline and follow-up calls were not considered part of MR and suspected to influence readmissions and health care utilization. 20, 21 Thus; these were excluded to avoid bias in favor of the intervention.
Study selection and data extraction
Screening of titles and abstracts for relevance and data extraction was performed independently by two authors; EH and AB. Discrepancies were discussed to obtain consensus, disagreement was resolved by a third author (DB).
Abstracted data were related to study design, authors, country of correspondence, year of publication and setting, study population, number of participants, demographics and baseline comparability if applicable. Details of the study intervention, including who and when implemented MR and what comprised the MR service, and the standard care in the study site, were extracted. Studies evaluating complete MR performed by pharmacy staff in a hospital setting were relevant to the review. Non-pharmacy-led MR was considered out of the scope of this review. Studies were divided into two subsets: those in which MR was the primary element of the intervention and labeled as "primarily MR" studies, and studies in which the MR intervention was performed in bundle with other non-MR health care activities. The latter were labeled as "supplemented MR" studies. This classification was to enable better understanding of the dynamic of MR practice and the true impact of MR on patient outcomes and health costs.
Outcomes and cost estimation
Details related to the effect of MR were recorded as processoriented outcomes such as medication discrepancy rate, clinical significance of medication discrepancy and resources necessary to implement MR including time and training. Patient-oriented outcomes included health resource use in hospital and community, health related quality of life and mortality rate.
Costs related to the extra time commitment needed to implement MR and savings due to reductions in medicines taken during the hospital stay were extracted. Cost savings related to hospital and emergency department revisits, health resource use in community and the time of doctors and nurses freed from obtaining accurate medication histories, and transcribing medications changes were extracted.
High heterogeneity due to disparate study designs and measured of outcomes deemed meta-analytic data reporting inappropriate. However, where a common unit of outcome measure we reported the effect and/or costs was pooled. The central tendency and range/SD were estimated using Microsoft Excel (Microsoft, Seattle, Washington). This approach has been used in similar systematic reviews. 17, 22 Cost estimation Pooled outcomes were valued in monetary units using the unit costs reported by personal social services research units and Department of Health reference costs in UK for the financial year 2012/2013, available at: www.pssru.ac.uk/. The average cost per patient was calculated for each pooled outcome by multiplying the pooled health resource consumed/saved by the relevant average unit cost.
Assessing risk of bias
Two of the investigators independently assessed risk of bias using a tool based on the Cochrane Collaboration risk of bias tool for randomized controlled studies. 23 In addition to the Cochrane risk domains for randomized controlled studies, the following risk domains were assessed: design, baseline comparability, standardized intervention delivery and outcome measurement and sample size calculation. These domains were to enable more comprehensive evaluation for the quality of non-randomized and uncontrolled studies. The tool was piloted and validated to fit the purpose of this review (Appendix 2); it was presented to researchers with systemic review experience from different disciplines. They were invited independently to assess the quality of two articles using the tool and provide interactive feedback via group and one to one discussions. Disagreements were referred and resolved by a third reviewer (DB). This review registration number at the international prospective register of systematic reviews (PROSPERO) is CRD42012002386. 
Results
The literature search identified 4065 citations, of which 13 met the inclusion criteria. The study selection process and number of papers excluded at each stage of the review are summarized in Fig. 1 . Studies were most frequently excluded because they were not pharmacy-led and were not evaluating complete MR. Box 1 highlights the composite of MR practices across a selection of excluded articles.
The majority of studies were conducted in Europe of which three were in Northern Ireland. 24e26 Five studies were based in the USA and Canada 27e31 and one study in Australia. 32 One study was reported in French 33 and the remainder were in English. Table 1 summarizes the characteristics of included studies with respect to study design. There were seven controlled studies 24,26e29,32,34 of which three were randomized, 26, 27, 30, 32 one non-randomized prospective observational 24 and three before and after study designs. 28, 31, 34 The remaining were prospective uncontrolled studies. 25, 29, 33, 35, 36 A detailed description of comparators and the study inclusion criteria are also presented in Table 1 . It can be seen that what constituted a standard care varied across the reviewed studies. Table 2 summarizes the composite of the reviewed interventions. Four studies were primarily MR. 28, 29, 33, 35 The remainder were supplemented MR. MR was often bundled with pharmacotherapy consultation or medication review, patient consultation and discharge planning. Patients were very similar in terms of demographic characteristics. Average age ranged between 55 and 93 years and equal male to female ratio. Patients were prescribed a mean (SD) of 7 (4.3) medicines. Characteristics of included patients are summarized in Box 2.
Quality of the evidence
Outcomes of bias assessment by study and type of bias are presented in Figs. 2 and 3 , respectively. Studies were considered at high risk for design bias particularly randomization and allocation concealment. Risk of bias in terms of selection was often low, specifically in relation to baseline comparability and patient selection (10 out of 13). Performance bias with respect to delivery of the intervention and outcome measurements was generally low (9 out of 13). Detection bias was low for five studies, 25e27,32,34 and most studies were considered not susceptible to selective reporting (11 out of 13). Only five studies introduced no concerns regarding the adequacy of the study power and the statistical analysis. 26, 27, 30, 34, 36 Effects of pharmacy-led MR Anderegg et al 31 reported a significant reduction in 30 day readmission rate for patients with high risk; 5.5% (P ¼ 0.042). Those were patients hospitalized with acute myocardial infarction, congestive heart failure or pneumonia and chronic obstructive pulmonary disease and on oral anticoagulation. At three months, the reduction in readmission and emergency department visits ranged from 6.4% to 9.3%. 27, 34 This effect was statistically significant (P ¼ 0.045 and 0.047, respectively). However, the effect was not significant at six months post discharge. 27 At twelve months post discharge, Scullin et al found a significant reduction readmissions rate in the intervention group compared to the control group. Patients also took longer time to be readmitted; 262 days and 242 days, respectively.
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There was a mixed effect of MR on hospital stay with a pooled median (IQ) increase in hospital stay of 8.4 (0, 16) Health resource use in community and heath related quality of life were evaluated by only one Australian study using a postal survey 30 days post discharge. 32 The total number of health visits and resource use post discharge was significantly lower in the intervention group. Mortality at 12 months was assessed by three studies, none identified a significant impact. Two studies estimated savings related to the time of other members of the health care team. 24, 28 The time spared for doctors and nurses was 14 min per patient 24 and 1 h, respectively. 28 However, this was not valuated in monetary units.
Cost estimation
The valuation of doctor and nurse time using the reference unit cost reported by the Personal and Social Services Research Unit in the UK for the year 2012/2013, estimates savings of £85 (USD $121.08) per patient in nurse time and £8.75 (USD $12.46) per patient for doctor time. The average cost of pharmacist time to implement MR would be £14.7 (USD $20.93) (£13.8e£49.2; USD $19.65eUSD $70.08) per patient. The average costs of excess hospital stay can be estimated as £92.4 (USD $131.62) (£0e£176; USD $0e$250.70). Savings in terms of preventing readmissions at 30 days post discharge can be estimated at £5744 (USD $8182) (£2872e£8472; USD $4091e$12,068). At three months, savings can be estimated as £1344 (US $1914) (£9190e£13,354; US $13,090eUS $19,022).
Discussion
MR is a well-defined process and recommended to take place each time the patient is transferred between health settings or different levels of care within the same setting.
1,2,4,10,11,19 However, MR is prioritized and delivered differently across countries and health organizations. 10, 11, 19 Thus, the composite of the optimum practice of MR is not widely standardized and requires further discussion among health professions and organizations. The current review identified only a limited number of studies; 13 implemented MR fully from admission until discharge and communicated updated information to the next health provider. In some institutions and health care systems, MR is delivered at admission namely through medication history-taking, or simply at discharge alone or bundled with more specialized service such as medication review. 37, 38 MR provided at one end of patient care or transfer was considered incomplete in this review. Additionally, MR is often bundled with pharmacotherapy consultation and reviews, 25e27,30,35,36 and discharge counseling. 25, 27, 28, 30, 31, 33, 35, 36 MR appears to be a multidisciplinary and multidimensional health process; i.e. it requires collaboration of various health providers at various care levels. Thus, MR can be integrated with a multicomponent care bundle designed to improve patient outcomes. Hence, the relevance of assessing MR effects in isolation of other care activities might be questionable in some contexts, and implementation of MR fully faces number of challenges. This has been highlighted in a number of professional and health management meetings. 19, 39 Therefore, developing a well-defined MR process and highlighting the role of pharmacists in optimizing the delivery and application of MR are needed. Further research and discussion among health care systems and world organizations to encourage organizations to define their own MR process and adopt MR within their routine workflows is warranted. This review highlighted that continuity of care was improved by MR pharmacist intercepting and clarifying medication discrepancies. 28, 29, 33, 35 However, these discrepancies were not always considered clinically significant, and thus little can be said as to whether intercepting MR discrepancies precludes actual patient harm. This corroborates previous MR reviews requesting future studies to focus on evaluating actual harm and patient-oriented outcomes. 17, 18, 40 Kwan et al, 17 suggested that MR alone probably does not reduce post discharge hospital utilization but may do so when bundled with interventions aimed at improving care transitions. This review ▪ Admission reconciliation 15 min (IQR 10e21) ▪ Time required for discharge reconciliation was not record found the evidence is lacking and was of poor quality, precluding confirmative conclusions for the effects of MR alone or when bundled with other care activities. Without detailed investigation of the nature of each unit of resource used, it is not possible to draw definitive conclusions. Thus, the effects on readmissions, length of hospital stay, post discharge health resource use, mortality and quality of life will remain uncertain unless these details were collected compressively.
Strengths and limitations
There is no other comprehensive review that scoped effects and costs of implementing full MR and highlighted the features of MR practice in the context of non-MR health care activities. The empirical valuation for the costs of MR was useful to highlight the potential cost drivers and data needed to conduct useful cost/costeffectiveness evaluation in future. This review implemented a comprehensive search strategy by independent reviewers. All key terms systematically were searched through all relevant databases, key authors and institutions with no limitations to study language, year of publication or design. No other MR review implemented a comprehensive quality assessment that enable the reader to understand the quality of each study and weighted them differently based on the robustness of their findings.
However, this systematic review is subject to a number of limitations. The reviewed studies were limited and of inadequate quality. They were mainly non-randomized and/or uncontrolled designs. Additionally, the composite of the reviewed interventions varied widely and represented very heterogynous MR practice. Thus, the generalizability of this review must be considered in light of the differences existing between worldwide health care systems, processes for sharing information, and funding of patient care. 41 
Conclusion
This review provided an empirical valuation of MR costs and highlighted that the extra time commitment to implement MR and details of post discharge resource use are potentially the main cost drivers to inform policy makers as to the cost implications of MR. Research focused on evaluating cost-effectiveness of pharmacy-led MR should be a priority because evidence is scant. Providing a comprehensive pharmacy-led MR service to patients may be desirable; however, it is essential to identify the situations most likely to benefit from pharmacy-led MR and to target areas where MR impact is maximized.
1. Design bias (focus study question & design)
The study clearly described all of the following: Targeted population The intervention The comparator Outcomes measured The study design is the best to answer the question, e.g. RCT for intervention The study addressed the intended research question
The study is not fulfilling any of these criteria Insufficient information to permit judgment of 'Low risk' or 'High risk'
Selection bias (external and internal variations)
The study sample is representative of the intended population There is nothing special about the sample with any potential to effect intervention or outcomes All patients were included/excluded as per the stated inclusion and exclusion criteria The study groups are comparable at baseline The investigators used a standardized process which followed by all the service providers delivering the intervention 6 The process of intervention delivery was not standardized Insufficient information to permit judgment of 'Low risk' or 'High risk' 6. Performance bias (Standardized outcome measurement)
The investigators used a standardized process which followed by all investigators recording and measuring the outcomes 7 The process for recording/measuring outcomes was not standardized All pre-specified (primary and secondary) outcomes have been reported The reported outcomes are appropriate to answer the study question
The study is not fulfilling any of these criteria Insufficient information to permit judgment of 'Low risk' or 'High risk' 9. Adequacy of study power (appropriate Statistical analysis)
The study used appropriate/justifiable statistical testing Power calculation or sample size calculation was performed Results do not match up or add up but with no major concern
Explanatory notes: 1. For example, groups were reported comparable but with no evidence to support this or groups reported different but no way of knowing if this is significant. 2. For example referring to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice or drawing of lots. 3. For example generating sequence by odd or even date of birth, sequence generated by some rule based on date (or day) of admission, sequence generated by some rule based on hospital or clinic record number or other non-random approaches such as allocation by judgment of the clinician, the preference of the participant, on the results of a laboratory test or a series of tests or the availability of the intervention. 4. For example the study allocation was concealed by central allocation (including telephone, web-based and pharmacy e controlled randomization), sequentially numbered drug containers of identical appearance or sequentially numbered, opaque, sealed envelopes. 5. For example the study allocation based on using open random allocation schedule (e.g. a list of random numbers), assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or not sequentially numbered, alternation or rotation, date of birth, case recorded number or any other explicitly unconcealed procedure). 6. For example the investigator used a standardized form or checklist or undertook a training. 7. i.e. the investigators used a structured review of medical chart, independent and double identification of medication discrepancies and demonstrate satisfactory agreement between the intervention assessors. 8. Detection bias criteria related to blinding of outcomes is considered of importance in assessing the measurement of medication discrepancies and their clinical significance. However, blinding of outcome assessors not particularly relevant to the end-points of hospital revisits or deaths and therefore it was assessed whether studies confirmed outcome data by using a subjective standardized reporting system such as hospital data or self-report data. 9. i.e. attrition rate is similar between study groups, the study follow up is complete, patients were analyzed as allocated at the study commencement, reasons for missing outcome data unlikely to be related to true outcome, missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. In case of dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate. For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size and missing data have been imputed using appropriate methods.
